Clinical Focus Target CNS disorders with PAS-004 MEK inhibitor portfolio; potential opportunities to collaborate with neurology clinics, research groups, and patient advocacy coalitions focused on NF1 and MAPK-driven diseases.

Clinical Partnerships Active engagement in conferences and poster presentations (ESMO, NF conference) indicates openness to collaboration; use conferences to schedule early BD outreach with investigators, trial sites, and biotech partners.

Stage & Needs Clinical-stage biotech with Phase 1/1b data seeking partnerships, co-development, or licensing deals to advance PAS-004 into broader trials or rare-disease programs; align value propositions to potential acquirers or strategic partners.

Financial & Scale Funding runway and revenue signals suggest opportunistic financing or non-dilutive grants; propose partnership structures that minimize upfront costs while accelerating development and market access.

Executive Access New CMO appointment with growth-driven leadership; leverage to initiate high-touch outreach to clinical development, translational medicine, and commercial strategy contacts for joint development discussions.